Equillium (NASDAQ:EQ) reported quarterly losses of $(0.41) per share. This is a 32.26 percent decrease over losses of $(0.31) per share from the same period last year.
RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target
RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.